Twist Bioscience Corporation (TWST) makes synthetic DNA on silicon chips, selling synthetic genes, next-generation sequencing target-enrichment tools, oligo pools and antibody discovery services to drug developers and academic labs. The stock traded at $102.41 in morning action, down 8.25% from the previous session's close of $111.62, with the direction unambiguously negative. Shares had indicated a milder decline near $106 in pre-market trading before opening at $102.50 and staying pinned close to the low. No new press release, filing or macro release explained the slide; the decline is a continuation of the selling that followed the company's fiscal 2026 fourth-quarter report and the valuation debate it triggered.
The Nov. 12 report itself was solid. Revenue rose 28% to $126.6 million, ahead of the $123.6 million consensus, and adjusted EBITDA turned positive at $2.2 million — a milestone management had promised. Full-year revenue reached a record $459.4 million, up 22%.
The problem was the outlook. Fiscal 2027 guidance of $550 million to $560 million implies total growth of roughly 20% to 22%, with about $100 million from AI-enabled drug discovery — around 69% growth versus 175% in fiscal 2026. For a stock that had nearly quadrupled during 2026, that deceleration was the trigger. Shares have not recovered since, and the pattern of failed rebounds — including a 3.9% bounce on Nov. 18 and a reversal on Nov. 19 that closed 4.07% lower — left the stock vulnerable to further liquidation once support gave way.
Sell-side estimates have been recalibrated sharply, and the cuts kept accumulating this week. Barclays trimmed its target to $130 from $215, UBS to $120 from $190, Jefferies to $125 from $150, Baird to $135 from $187, Guggenheim to $150 from $212, Canaccord to $150 from $205 and TD Cowen to $137 from $190. The common thread is a lower multiple applied to forward revenue and concern that execution must now prove the AI franchise is additive rather than a substitute for slower core growth.
Even after the decline, the equity remains valued at roughly $7 billion, or close to 12 times the midpoint of next year's revenue guidance net of about $582 million in cash — a multiple that assumes sustained high growth. That math is what keeps sellers active on rallies.
Disclosure flow has added to the pressure. Recent Form 144 and Form 4 filings showed chief executive Emily Leproust selling shares, including roughly 19,000 shares reported in mid-November. While programmatic sales are routine, they land poorly during a valuation reset. A Nov. 5 report from short-seller The Bear Cave arguing the share price had outrun fundamentals produced an 11% to 12% one-day drop and never fully left the narrative.
Activity has been heavy. The stock averages about 2.5 million shares a day, and recent down sessions have traded at or above that pace, including 2.5 million on Nov. 12 and 2.25 million on Nov. 19 — evidence of broad distribution rather than a single large print. Today's action opened with a gap lower and little intraday recovery, a signature of persistent supply.
TWST is the clear laggard within its small-cap biotech and life-science tools cohort, which is trading with a much smaller spread. Technically, the shares are now well below their 30-day moving average near $160 and beneath the 100-day average, with only the rising 200-day line — around $90 at the start of the month — providing a distant floor. The stock sits roughly 53% below its 52-week high of $219.71 but remains up more than 250% year to date.
The score runs from 0, meaning no meaningful news and a normal price move, to 100, meaning transformative news and an extreme, rare move. This event earns 28 out of 100.
The verified news was moderate: no new disclosure today, but a genuine fundamental reset in fiscal 2027 guidance plus a cluster of analyst target cuts at a premium valuation. The price move was only about 1.6 times the stock's typical daily swing of roughly 5.3% over the past three months, and moves of this size or larger occurred 13 times in the last 69 sessions. Modest news and an unremarkable move combine into a low score.
The next hard catalyst is the fiscal first-quarter report, expected in early February, where investors will test whether AI drug discovery revenue can sustain a quarterly pace above $25 million. Management is also scheduled to appear at the Evercore health conference on Dec. 1, offering another opportunity to clarify the capacity expansion and $150 million, two-year capital plan funded from existing cash.
Consensus remains constructive — a Buy rating with an average target near $129 — but dispersion is wide. Risks include continued multiple compression, further estimate revisions, insider supply, and the possibility that core sequencing and synthetic biology demand grows slower than the guide assumes. Sentiment toward high-multiple small-cap growth names will likely matter as much as fundamentals in the interim.
Tickeron's Trending AI Robots page curates the strongest performing automated strategies under current market conditions, drawn from a library of hundreds of AI trading bots covering thousands of tickers. Bots differ by strategy logic, timeframe, performance metrics and the symbols they trade, so the featured list changes as market conditions shift. For traders who want quantitative signals alongside their own research, reviewing the current leaders is a practical next step.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
TWST moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend. In 28 of 29 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 90%.
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TWST as a result. In 62 of 76 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 82%.
The Moving Average Convergence Divergence Histogram (MACD) for TWST turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 37 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 86%.
The 10-day moving average for TWST crossed bearishly below the 50-day moving average on October 20, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TWST declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
TWST broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for TWST entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 49 of 63 cases where TWST's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 78%.
Following a +10.77% 3-day Advance, the price is estimated to grow further. Considering data from situations where TWST advanced for three days, in 235 of 291 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
The Tickeron Valuation Rating of 5 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (17.967) is normal, around the industry mean (3.596). P/E Ratio (-54.166) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (20.243) is also within normal values, averaging (443.347).
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. TWST’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 43 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 86 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TWST’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of proprietary semiconductor-based synthetic DNA manufacturing process
Industry Biotechnology